Drug Discovery World
SEPTEMBER 29, 2022
For these reasons and others, many biotech and pharmaceutical companies – along with government research labs and academic institutions – rely on contract research organizations (CROs) for drug discovery services. The company has the resources to complete the project in-house or it could outsource it to CROs.
The Pharma Data
SEPTEMBER 22, 2020
Swiss pharma company to acquire biotech for $449m (€380m). Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). Activated NLRP3 is involved in the production of pro-inflammatory cytokines IL-1?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. Cambridge is a focal point for many pharmaceutical companies working in this therapeutic area.
Drug Discovery World
NOVEMBER 15, 2022
If a pharmaceutical company is racing to identify a new vaccine, for instance, then waiting for three weeks to receive DNA sequences each time can slow down the development process compared to competitors who might have faster timelines.” . The longer the DNA gets, the longer it will take for labs to receive it,” notes Dr Daniels.
Drug Discovery World
JANUARY 26, 2023
However, coming off the back of high levels of return on investment (ROI) seen throughout Covid-19 and therefore 2021, was always going to be difficult for the pharma industry. As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities.
Drug Target Review
MAY 23, 2023
Algae – an overlooked resource for new therapies It is only in recent years that algae research has expanded beyond their potential for producing biodiesel, to also consider them as a bio-resource, not only for novel prebiotics but also for compounds with unique structures and pharmaceutically relevant bioactivities.
Drug Target Review
APRIL 19, 2024
The discovery of the folding intermediate states to target has been enabled by our proprietary computational platform, and the development of small molecule folding interfering degraders is now accelerated by a proprietary AI platform. We are now in the preclinical stage of developing a proprietary drug pipeline.
Expert insights. Personalized for you.
130 
Let's personalize your content